Share:
Original Article

Association of Flame-Retardant Clothing with Mycosis Fungoides: A Retrospective Analysis

Author Affiliation(s)

Abstract

Introduction: Mycosis fungoides (MF), the most prevalent form of cutaneous T-cell lymphoma (CTCL), has been associated with a variety of environmental and occupational exposures. Flame-retardant clothing (FRC), in contrast to flame-resistant clothing, is chemically treated and may constitute a previously unrecognized occupational hazard.

Objectives: To report an association between FRC and MF.

Methods: After encountering several young male patients whose onset of MF coincided with the occupational use of FRC and occupation as fire fighters, we did a retrospective search. Additional biopsy proven MF patients with use of FRC were identified by the EPIC electronic medical record using the search terms “CTCL, mycosis fungoides, flame, and flame-retardant.”

Results: Eight MF patients, all males, ranging in age from 31 years to 64 years (median age, 35 years) with exposure to FRC were identified. MF remission was noted in three patients who discontinued FRC use and in one patient who used a cotton undershirt barrier, while disease persistence was noted in one patient who continued to use FRC.

Conclusions: FRC appears to be associated with development of MF through chronic antigen stimulation. Use of FRC is an occupational hazard for fire fighters. Any patient whose MF coincides with use of FRC should avoid further exposure through avoidance or switching to clothing made from inherently flame-resistant fibers.

Keywords : Mycosis fungoides, cutaneous T-cell lymphoma, flame-retardant clothing, flame-retardant chemicals, occupational-related exposure

References

1. Beyer M, Möbs M, Humme D, Sterry W. Pathogenesis of Mycosis fungoides. J Dtsch Dermatol Ges. 2011;9:594–598. DOI: 10.1111/j.1610-0387.2011.07635.x. PMID: 21371258. 2. Tan RS, Butterworth CM, McLaughlin H, Malka S, Samman PD. Mycosis fungoides--a disease of antigen persistence. Br J Dermatol. 1974;91:607–616. DOI: 10.1111/j.1365-2133.1974.tb12449.x. PMID: 4281316. 3. Jackow CM, McHam JB, Friss A, Alvear J, Reveille JR, Duvic M. HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma. J Invest Dermatol. 1996;107:373–376. DOI: 10.1111/1523-1747.ep12363352. PMID: 8751973. 4. Wohl Y, Tur E. Environmental risk factors for mycosis fungoides. Curr Probl Dermatol. 2007;35:52–64. DOI: 10.1159/000106410. PMID: 17641490. 5. Slodownik D, Moshe S, Sprecher E, Goldberg I. Occupational mycosis fungoides - a case series. Int J Dermatol. 2017;56:733–737. DOI: 10.1111/ijd.13589. PMID: 28255994. 6. Ghazawi FM, Netchiporouk E, Rahme E, et al. Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy. Cancer. 2017;123:3550–3567. DOI: 10.1002/cncr.30758. PMID: 28493286. 7. Ghazawi FM, Alghazawi N, Le M, et al. Environmental and Other Extrinsic Risk Factors Contributing to the Pathogenesis of Cutaneous T Cell Lymphoma (CTCL). Front Oncol. 2019;9:300. DOI: 10.3389/fonc.2019.00300. PMID: 31106143. PMCID: PMC6499168. 8. Moreau JF, Buchanich JM, Geskin JZ, Akilov OE, Geskin LJ. Non-random geographic distribution of patients with cutaneous T-cell lymphoma in the Greater Pittsburgh Area. Dermatol Online J. 2014;20:13030/qt4nw7592w. PMID: 25046454. 9. Litvinov IV, Tetzlaff MT, Rahme E, et al. Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries. Cancer. 2015;121:1993–2003. DOI: 10.1002/cncr.29301. PMID: 25728286. PMCID: PMC4457714. 10. Litvinov IV, Tetzlaff MT, Rahme E, et al. Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries. Cancer Med. 2015;4:1440–1447. DOI: 10.1002/cam4.472. PMID: 26136403; PMCID: PMC4567029. 11. Aschebrook-Kilfoy B, Cocco P, La Vecchia C, et al. Medical history, lifestyle, family history, and occupational risk factors for mycosis fungoides and Sézary syndrome: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014:98–105. DOI: 10.1093/jncimonographs/lgu008. PMID: 25174030. PMCID: PMC4155463. 12. Shaw SD, Blum A, Weber R, et al. Halogenated flame retardants: do the fire safety benefits justify the risks? Rev Environ Health. 2010;25:261–305. DOI: 10.1515/reveh.2010.25.4.261. PMID: 21268442. 13. Andersen KE. Sensitivity to a flame retardant, Tris(2,3-dibromopropyl)phosphate (Firemaster LVT 23 P). Contact Dermatitis. 1977;3:297–300. DOI: 10.1111/j.1600-0536.1977.tb03690.x. PMID: 606484. 14. Parlew R, King CM, Evans S. Primary sensitization to a single accidental exposure to a flame retardant and subsequent allergic contact dermatitis. Contact Dermatitis. 1995;33:286. DOI: 10.1111/j.1600-0536.1995.tb00499.x. PMID: 8654099. 15. Flame Retardants [Internet]. [cited 2021 Aug 26]. Available from: https://www.niehs.nih.gov/health/materials/flame_retardants_508.pdf Accessed on 26 August 2021. 16. Costas L, Infante-Rivard C, Zock J-P, et al. Occupational exposure to endocrine disruptors and lymphoma risk in a multi-centric European study. Br J Cancer. 2015;112:1251–1256. DOI: 10.1038/bjc.2015.83. PMID: 25742473. PMCID: PMC4385964. 17. Garg N, Rayan J, Adams M, et al. Newsearch: An architecture for fast analytic search of electronic medical records. Available from: http://garglab.com/projects/ehr-search. Accessed on 26 August 2021. 18. Hughes MF, Edwards BC, Mitchell CT, Bhooshan B. In vitro dermal absorption of flame retardant chemicals. Food Chem Toxicol. 2001;39:1263–1270. DOI: 10.1016/s0278-6915(01)00074-6. PMID: 11696400. 19. Liu X, Li W, Yuan H, Gu W, Chen D. Surgical treatment of rare giant malignant tumors of the scalp: A report of 3 cases with different tumor types. Oncol Lett. 2016;12:3411–3416. DOI: 10.3892/ol.2016.5113. PMID: 27900013. PMCID: PMC5103960. 20. McConnell DC, Harris TJ, Tucker SB. Fire-retardant clothing-related dermatitis. Dermatitis. 2012;23:27–31.DOI: 10.1097/DER.0b013e31823d18ef. PMID: 22653066. 21. Effects of Laundering | DuPontTM Nomex® TA Newsletter Volume 1 [Internet]. [cited 2021 Aug 26]. Available from: https://safety.dupont.com/LP=6862. Accessed on 26 August 2021.

Send mail to Author


Send Cancel